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The  expression  of  immunoglobulin genes  is  usually  unstable  in  mouse 
myeloma cells (1, 2).  Some cell lines spontaneously lose the ability to produce 
immunoglobulin heavy chain at a rate of 1 ×  10-3/cell/generation (3). One cell 
line, P3 (MOPC 21), has yielded spontaneous variants which synthesize altered 
heavy chains.  Adetugbo and co-workers have examined 7,000  P3 clones and 
have identified four such variants, three of  which have deletions, and one which 
has a point mutation (4). 
After mutagenesis of the MPC 11 mouse myeloma cell line, as many as 2-6% 
of the  surviving  cells  are  variants  in  heavy  chain  production,  of which 
approximately two-thirds have ceased synthesis of heavy chains while continu- 
ing light chain production (5). The remaining third of these MPC 11 variants 
synthesize altered  heavy chains  and  are  divided about evenly between two 
major types: (a) those synthesizing heavy chains shorter than the parent (5); 
and (b) those synthesizing heavy chains which lack the 72b serologic determi- 
nants of the parental heavy chain but which express serological determinants of 
the v2a subclass (6). 
Identification of the original primary variants which produced a v2a heavy 
chain was based on serology, assembly patterns, and peptide maps (6). Recently, 
chemical characterization and partial amino acid sequence determination of one 
~/2a variant protein has shown that the Fc portion of its heavy chain is distinct 
from that of MPC 11, the parental IgG2b immunoglobulin, and is identical to 
that of MOPC 173 (7), an IgG~a  (K) mouse myeloma protein of known sequence 
(8). These v2a variant heavy chains are identical in size to the parent with the 
exception of one, which is larger.  The latter variant gives rise to secondary 
variants producing-/2a heavy chains of normal size (9). Additional secondary 
variants producing ~/2a heavy chains of normal size have been derived from 
variants synthesizing short heavy chains (9, this paper). 
Previous instances of the production of a  new subclass in immunoglobulin- 
producing cells have been reported. For example, Hausman and Bosma have 
described two cases in which myeloma tumors ceased production of the original 
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heavy or light chain and began synthesis of a new chain differing in subclass or 
type,  and  binding  of idiotype  (10). However,  both  these  changes  appeared 
during adaptation to continuous in vitro culture by alternate passage between 
culture and animal,  and the origin of the variant cell was thus in doubt.  In 
addition,  Kunkel et al.,  Natvig and Kunkel,  and Werner and Steinberg have 
observed  the  presence  in human  serum  of "hybrid" immunoglobulins  which 
contain antigenic determinants of two heavy chain subclasses (11-13).  A similar 
observation has been made in mice (14). 
We do not know what genetic or biochemical mechanisms are responsible for 
the instability of immunoglobulin expression in mouse myeloma cells or if this 
instability is related to any of the normal events in the regulation of antibody 
production.  Since the ~/2a variants  arise  frequently,  either directly from the 
parental cell line or as secondary variants from variants producing short heavy 
chains,  and are expressing either part or all of a gene that was silent in the 
parent, a more detailed study of these variants should provide some insight into 
the structure of the immunoglobulin genes and the genetic control of immuno- 
globulin  expression.  In  this  paper,  we  examine  the  relationship  of the 72a 
variants to each other and to their parent. 
Materials and Methods 
Cell Lines and Tumors.  All cell lines used in this study are summarized in Table I. The cell 
line, 45.6.2.4,  was derived from the BALB/c mouse myeloma tumor, MPC  11, which synthesizes 
an IgG2b (K) immunoglobulin (15).  Primary (6) and secondary (9) variants synthesizing IgGza (K) 
immunoglobulins  were  obtained  from  MPC  11  by  using  a  cloning technique  (3).  Additional 
variants synthesizing IgG2a (K) have been isolated during the course of these studies. ICR 4.68.66 
and ICR 4.68.110 are secondary variants derived from the short heavy chain producing variant, 
ICR 4.68. U2 arose spontaneously. The parental cell line and all variants retained tumorigenicity, 
both as  solid  tumors  and  ascites.  Cell  lines  were  grown  in  suspension  culture  in  Dulbecco's 
modified Eagle's medium (Grand Island Biological Co., Grand Island, N.Y.),  supplemented with 
20%  heat  inactivated  horse  serum  (Grand  Island  Biological  Co.,  or  Flow  Laboratories,  Inc., 
Rockville, Md.), nonessential amino acids, L-glutamine (3.33 mM), penicillin (10,000 U/liter), and 
streptomycin sulfate (50 mg/liter), all purchased from Grand Island Biological Co.  MOPC  173, a 
gift from Dr. Melvin J. Bosma, Institute for Cancer Research, Philadelphia, Pa. and LPC 1, a gift 
of Dr.  Michael Potter, NIH,  Bethesda, Md., both IgG2a  (K), were maintained in BALB/c mice. 
Preparation of Antisera.  Rabbits were immunized by numerous intradermal injections in the 
flanks and footpads with a  total of 100-250  /~g protein emulsified by sonication in 1 ml of 50% 
complete Freud's adjuvant (Difco Laboratories, Detroit, Mich.). After 3 wk, rabbits were boosted 
with  an intravenous injection (1  ml) of 100  /xg protein coated onto 300  /zg  alumina particles. 
Beginning 1 wk after boosting, rabbits were bled twice a  week until the antibody titer fell. The 
antisera were prepared against immunoglobulin from MPC  11  (IgG2~),  LPC  1 (IgGo~),  and ICR 
9.9.2.1  (secondary variant,  IgG2a),  and the Fc fragments of immunoglobulin from MPC  11  and 
LPC  I.  Commercial  antisera  directed  against  the  different  classes  and  subclasses  of mouse 
immunoglobulins were obtained from Meloy Laboratories, Inc., Springfield, Va. Their specificity 
was confirmed by using a  panel of myeloma proteins. 
Purification  ofImmunoglobulin.  Cells were injected intraperitoneally into pristane (2,6,10,14- 
tetramethyl-pentadecane,  Aldrich Chemical  Co..  Milwaukee,  Wis.)  primed  BALB/c mice  (16). 
The ascites from the tumor-bearing mice were collected, centrifuged to remove cells and debris, 
treated at 56°C for 30 min, and stored frozen. The presence of paraprotein was verified by cellulose 
acetate  microzone electrophoresis  (Beckman  Microzone Electrophoresis  System,  Bulletin  7086, 
Beckman Instruments, Inc., Fullerton, Calif.). 
The  myeloma  protein  was  precipitated  with  ammonium  sulfate  as  described  (17).  Further 
purification  was  carried  out  by  using  ion  exchange  chromatography  on  a  column  of DEAE- 
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modification of  Potter's  system (17).  The starting  buffer  was 0.005 M  Tris-phosphate  pH 8.6,  and 
the final  buffer was a 4:1 mixture of  0.005 M  Tris-phosphate, pH 8.6,  and 0.5 M  Tris-phosphate, 
pH 5.1.  The purified  protein was dialyzed against distilled  water and freeze-dried.  The purity of 
the proteins was verified  by microzone electrophoresis, immunoelectrophoresis,  and polyacryl- 
amide gel electrophoresis  in sodium dodecyl sulfate (SDS-PAGE) ~  (18). 
Radioimmunoassay 
PREPARATION OF  ~MMUNOADSORBENT COLUMN.  Sera from normal mice, mice bearing MOPC 
141  tumor,  and mice bearing MOPC  195 tumor  (both IgG2b, K) were pooled and mixed with an 
equal volume of phosphate-buffered  saline  (0.15  M NaC1,  0.02  M sodium phosphate,  pH 7).  The 
serum pool was brought  to 40% saturation  by the addition of saturated  ammonium sulfate and 
stirred at 4°C for 30 rain.  The precipitated  proteins were dialyzed against  0.25  mM phosphoric 
acid-40 mM Tris and applied to a column of DEAE cellulose (DE-52,  Whatman),  equilibrated in 
the same buffer.  The IgG fraction was eluted with 12.5  mM phosphoric  acid-250 mM Tris and 
coupled  to  Sepharose  4B  (19). The  resulting  immunoadsorbent  contained  3.72  mg of IgG/ml 
Sepharose. 
PREPARATION OF  ANTI=IDIOTYPIC ANTISERA.  Rabbit  antisera  against  immunoglobulin  from 
MPC 11 (R132) or ICR 9.9.2.1 (BB 24) were brought to 0.5 M in NaC1 and chromatographed in this 
solution on the immunoadsorbant  column to which normal IgG and IgG2b,  K-myeloma proteins 
had been attached.  The eluted (unbound)  fractions were tested by Ouchterlony analysis against 
the immunizing antigen and normal mouse serum, MOPC 195, MOPC 141, and MOPC 173. Those 
fractions from R132 that were reactive only against the immunizing antigen MPC 11, and those 
fractions from BB 24 which were reactive only against the immunizing antigen ICR 9.9.2.1, were 
pooled, and concentrated, when necessary, by dialysis against Sephadex G-200  (Pbarmacia Fine 
Chemicvls, Div. of Pharmacia Inc., Piscataway,  N.J.). 
PREPARATION OF  RADIOLABELED MPC  11  IMMUNOGLOBULIN.  MPC  11  cells (10~/ml)  were grown 
for 24 h  in Spinner medium  (20) containing  1/10 the normal concentration  of methionine,  10% 
heat inactivated horse serum, and 100/~Ci of 3:'S-methionine/ml (New England Nuclear, Boston, 
Mass.). 200/~g/ml of unlabeled methionine were added to the supernate to replace nonspocifically 
absorbed  [*-'S]methionine. The supernate  was then dialyzed against  phosphate-buffered  saline. 
We used the radiolabeled MPC 11 preparation without further purification since we found that it 
behaved identically to chromatographically purified radiolabeled protein in the radioimmunoas- 
say. 
RADIOIMMUNOASSAY.  The solid phase  radioimmunoassay  of Bosma et al.  (21) was  followed 
except that bound radioactive proteins were released from the polystyrene tubes by sonication for 
10  min in  1 ml of 1%  SDS and  transferred  for counting to scintillation  vials containing  10 ml 
Aquasol (New England Nuclear). 
Electrophoresis in Agarose.  The Johansson  method  (22), as modified by Dr.  Chester Alper 
(personal communication) was used. The electrophoresis buffer (pH 8.6) was composed of 35.05 g 
sodium barbital and 5.5 g barbital in 4 liters. The fixing, staining, and destaining solutions were 
methanol:water:acetic acid (5:5:1, vol/vol/vol) with 0.02% Coomassie Brilliant Blue R-250 (Consol- 
idated Laboratories Inc., Chicago Heights, Ill.) added to the staining solution. 
Assembly oflmmunoglobulin.  Logarithmically growing cells (3  ×  10") were washed twice in 
Spinner  medium  minus  valine,  threonine,  leucine,  and  containing  2%  heat-inactivated  horse 
serum. The cells were preincubated in I ml medium for 5 min in a 37°C water bath. 5/~Ci each of 
[14C]L-valine,  -threonine,  and  -leucine were added  (New England  Nuclear)  and  the cells were 
incubated further for 15 min. The incorporation of radioisotopes was stopped by immediate cooling 
of the cells in an ice bath and the addition of I ml cold medium (4°C). The cells were collected and 
lysed as previously described  (5). Radiolabeled immunoglobulins were immunologically precipi- 
tated by an  indirect technique  (5) and  were analyzed by 5% SDS-PAGE.  Gels were dried and 
subjected  to  radioautography  on  Kodak  XR-5  film  (Eastman  Kodak  Co.,  Rochester,  N.Y.). 
Radioautographs  were scanned  {log mode) with a  reflectance fluorescence transmission  (RFT) 
scanning microdensitometer equipped with an automatic General Computing Integrator (Transi- 
dyne General Corp., Ann Arbor, Mich.). 
Preparation of Radiolabeled  Secreted Immunoglobulin.  Logarithmically growing cells were 
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washed twice in Spinner medium containing 1/40 the normal amount of valine, threonine,  and 
leucine, and supplemented with 10% heat inactivated horse serum. The cells were resuspended in 
the same medium at a final concentration of 5 ×  105 cells/ml, and 5 ml were placed in a Petri dish. 
Radiolabeled L-valine, -threonine,  and -leucine were added at 15  ~Ci 14C each, or at 25 ~tCi 3H 
each. The dishes were incubated at 37°C in 5% CO~ for 48 h, at which time the cells were removed 
by centrifugation,  the  immunoglobulin was  precipitated  from the  supernate  by the  sandwich 
technique, and heavy and light chains were prepared by using SDS-PAGE (5). 
A large quantity of radiolabeled ICR 9.9.2.1  immunoglobulin was prepared from 40 ml of cell 
suspension  in a  spinner  culture,  incubated  with 250  ~Ci each of |3H]L-valine, -threonine,  and 
-leucine. The supernate was dialyzed against phosphate-buffered saline to remove labeled amino 
acids  after  which  the  protein  was  precipitated  with  50%  saturated  ammonium  sulfate.  The 
precipitate  was  dissolved  in  phosphate-buffered  saline,  dialyzed  against  distilled  water,  and 
freeze-dried. The radioactivity in the precipitate was found exclusively in immunoglobulin (15). 
The protein was subjected to complete reduction and alkylation (23), and radiolabeled heavy and 
light chains were  separated  by gel filtration on a  column of Sephadex  G-100  (2.2  ×  180  cm), 
equilibrated with 4.5  M urea,  1 M propionic acid (24). Elution was monitored by radioactivity. 
The pooled peaks were freed of salts by passage through a column of Sephadex G-25,  coarse (3  × 
60 cm), equilibrated with 0.05 M formic acid. 
Papain Digestion.  Radiolabeled Fab and Fc of ICR 11.8 and M224 were isolated after papain 
digestion as described by Guyer et al.  (25). 
Ion Exchange Chromatography of Peptides.  A mixture of [3HI and  [~4C]labeled  proteins was 
subjected  to  digestion  by  sequential  additions  of trypsin  and  chymotrypsin.  The  freeze-dried 
enzymatic digest  (5)  was  dissolved in  1.5  ml of 0.3  M  pyridine-HC1,  pH  1.7,  and  the pH was 
adjusted to <pH 2 with glacial acetic acid. The peptides were applied to a  heated  (56°C), water- 
jacketed column (0.2  x  23 cm), packed with a Dowex-50 sulfonated polystyrene resin (SPHER1X, 
type XX907,  Phoenix Precision Instrument Co., Philadelphia,  Pa.)  (15),  which was equilibrated 
with 0.05 M pyridine-acetic acid, pH 3.13.  The peptides were eluted with a gradient generated in 
a  Varigrad  (VirTis Co., Inc., Gardiner,  N.Y.),  by using  110 ml each of the following pyridine- 
acetic acid buffers: (a) 0.05 M, pH 3.13; (b) 0.10 M, pH 3.54; (c) 0.20 M, pH 4.02; (d) 0.5 M, pH 4.5; 
and (e) 2.0 M, pH 5.0 (26). 200 fractions of 2.5 ml each were collected into glass scintillation vials, 
the pH was recorded, the buffer was evaporated in an oven, and 0.5 ml H20 and 10 ml Aquasol 
were added to each vial. The samples were counted in a Beckman scintillation counter (LS-230 or 
LS-233,  Beckman Instruments,  Inc., Fullerton, Calif.), with the isosets adjusted so that the spill 
from the 3H to the 14C channel was <0.001%, and the spill from the ~4C to the 3H channel was 7 +- 
1%. The data were corrected for background and spill, and plotted as cpm or percent of total counts 
vs. fraction number, by using a computer program developed for us by Mr. David Medford. 
Results 
Ouchterlony Analysis of  Parent and Variant Immunoglobulins.  Cytoplasms 
and secretions from cultured cells, and immunoglobulins purified from sera or 
ascites of tumor bearing mice were tested by double diffusion in agarose (5). All 
of the variants listed in Table I were y2a positive and y2b negative when tested 
with  subclass  specific  (Meloy  Laboratories  Inc.,  Springfield,  Va.)  antisera. 
These-/2a immunoglobulins showed "complete identity" with each other using 
a variety of antisera produced against MPC 11 (IgG~b, K), LPC 1 (IgG2a, K), the 
~/2a variant protein-ICR 9.9.2.1,  and the Fc fragments of MPC  1I and LPC 1. 
All the variants shared the same antigenic determinants with the parent and 
lacked some antigenic determinants which were present on MPC 11  (Fig.  la). 
When tested with an antisera raised against the Fc fragment of LPC 1 (IgG2~, 
K), the variants shared the same determinants, some of which were absent from 
the  parent  (Fig.  lb).  This  analysis  showed  that  at least  part  of a  different 
constant region gene is expressed in these variants and distinguished the ~/2a 
variant proteins as a  group from the parent y2b protein.  Since many  of the FRANCUS,  DHARMGRONGARTAMA~  CAMPBELL,  SCHARFF,  AND  BIRSHTEIN 
TABLE  I 
The ~2a Producing Cell Lines Derived from MPC 11 
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*Primary  *Secondary var- 
Parent  Mutagen  variant  iant 
Heavy chain 
Sero-  Secre- 
Size 
type  tion 
45.6.2.4  55,000  72b 
45.6.2.4  -  U2  55,000  72a 
a45.6.3.1  Melphalan  *M224  55,000  72a 
b45.6.3.1  Melphalan  M319.2  55,000  ~2a 
~45.6.2.4  ICR 191  $ICR 11.8  55,000  72a 
d45.6.2.4  ICR 191  ICR 16  55,000  ~/2a 
~45.6.2.4  ICR 191  ICR 9  75,000  ~/2a 
§ 
ICR 9.9 
45.6  ICR 191  ICR 4.68 







75,000  ~,2a  - 
'*  ICR 9.9.2.1  55,000  ~,2a  + 
*  ICR 9.9.1.6.7  55,000  ~2a  + 
50,000  -  - 
ICR 4.68.66  55,000  ~2a  + 
.  ICR 4.68.110  55,000  72a  + 
50,000  -  - 
*  ICR 11.19.2  55,000  72a  + 
p sICR 11.19.3  55,000  T2a  + 
* In the text, we use an abbreviated form of the cell lines starting with the letter M, or ICR. 
$ M and ICR indicate the variant was obtained after mutagenesis with Melphalan or ICR 191, 
respectively. 
§ An arrow indicates that the subclone was obtained without further mutagenesis, a, b, c, d, and 
e  were listed in Preud'homme et al.  (6)  as:  45.6.3.2.2  M224;  45.6.3.2.2  M319;  45.6.3.1  ICR  11; 
45.6.3.1  ICR 16; 45.6 ICR 9; respectively, fwas listed as 45.6.3.2  ICR 11 in Birshtein et al.  (5). g 
was listed as 45.6.3.2 ICR 11.19.$3  in Koskimies and Birshtein (9). 
antigenic determinants detected by these antisera  are in  the Fc region,  the 
serology of the variable region was examined directly. 
Idiotypic Analysis of Parent and  Variant Immunoglobulins  by Radioimmu- 
noassay.  Rabbit antiserum to MPC 11 (R 132) was absorbed on an immunoad- 
sorbent  column,  as  described  in  Materials  and  Methods.  This  anti-idiotypic 
antiserum bound to MPC 11, and the binding was not affected by normal mouse 
serum, two other IgG~b(K)proteins (MOPC 141 and MOPC 195) (Fig. 2), or the 
IgG2~ (K)  immunoglobulin,  MOPC  173  (Fig.  3).  In contrast,  proteins purified 
from six 72a-producing variants were identical to each other and to the parental 
MPC 11 protein in their ability to inhibit this binding to the radiolabeled MPC 
11 protein  (Fig.  3).  A  second rabbit antiserum (BB24)  was raised against the 
72a variant protein, ICR 9.9.2.1,  and was also made anti-idiotypic by appropri- 
ate absorption  (Materials and Methods).  In a  similar radioimmunoassay, but 1540  NEW  SUBCLASS  EXPRESSION  IN  A  MOUSE  MYELOMA  CELL  LINE 
FIG.  I.  Ouchterlony analysis of parent and IgG2a variant proteins.  A, ICR 9.9.2.1.  B, 
MPC  11 (parent).  C,  ICR 11.8,  D, M224. E,  ICR 11.19.2.  F, ICR 16.  a,  R 133  is  anti-MPC 11. 
b, BB 15 is  anti-LPC 1-Fc. 
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F1o.  2.  Inhibition  of the  binding of [~S]Met-MPC  11  to  anti-idiotypic antisera  (R  132) 
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Fro.  3.  Inhibition  of  binding  of  [~S]Met-MPC  11  to  anti-idiotypic  antisera  directed 
against  MPC  11 by purified IgG~a variant proteins.  •  MPC  11,  [] M224,  •  ICR 16,  O ICR 
11.8,  A  ICR 9.9.2.1,  •  ICR 4.68.66,  •  ICR 11.19.3,  ~  MOPC  173. 
FIG.  4.  Agarose  gel  electrophoresis  of ascites,  a,  ICR  4.68.66.  b,  ICR  11.19.2.  c,  ICR 
11.19.3.  d,  MPC  11.  e, ICR 11.8.  f, ICR 16.  g, M224.  h, ICR 9.9.2.1.  i, MOPC 173.  O-origin. 
The major protein band near the anode  is albumin. 
using a smaller set of proteins, MOPC 173 did not inhibit the binding of MPC 11 
to  the  second  antiserum  while  the  parent,  MPC  11,  and  two  variants,  ICR 
9.9.2.1  and  ICR  11.8,  inhibited  equally  well  (data  not  shown).  These  results 
showed  that  the  T2a  variant  proteins  contained  MPC  11  variable  region 
antigenic determinant(s). 
Electrophoretic  Migrations of Variant Proteins in Agarose Gels.  To try to 
discriminate between the variants,  we examined ascites from the different T2a 
producing variants,  from MPC  11,  and  from MOPC  173  by electrophoresis  on 
agarose  plates.  The T2a  paraproteins  from  the  variants  clearly  fell  into  two 
groups  (Fig.  4).  The  first  group  consisted  of the  secondary  variants  derived 
independently  from  two  primary  variants  (ICR  4.68  and  ICR  11.19)  which 
produced heavy chains with a  mol wt of 50,000  (Table I).  These  four proteins, 
three of which are shown in Fig.  4,  panels a-c,  were more negatively  charged 1542  NEW  SUBCLASS  EXPRESSION  IN  A  MOUSE  MYELOMA  CELL  LINE 
than the MPC 11 parental protein (panel d). The second group of six variants, 
four of which are shown, migrated similarly to MPC  11  (Fig.  4,  panels e-h). 
This group consisted of four primary variant proteins with heavy chains of mol 
wt 55,000 (three of which are shown in panels e-g) and the two secondary v2a 
producing variants derived from ICR 9, the primary variant which synthesizes 
a ~2a heavy chain of mol wt 75,000 (one shown in panel h). For reference, the 
protein from MOPC 173 (IgG2a  [K ]), which has a cathodal mobility, is shown in 
panel i.  These differences in electrophoretic mobility indicated that the ~2a 
variants were not identical and suggested that they might fall into subgroups 
based on their origins. This possibility was examined by comparative peptide 
map analysis. 
Peptide Analysis.  For a systematic analysis, the heavy chains of each v2a 
variant were compared to ICR 9.9.2.1, a secondary  V  2a producing variant whose 
primary structure we have studied (7).  2 ~4C-variant heavy chains were mixed 
with 3H-heavy chains from ICR 9.9.2.1 and digested with trypsin and chymo- 
trypsin; the resulting peptides were resolved by ion-exchange chromatography. 
The peptide maps of two primary variants, ICR 16 and ICR 11.8, each vs. ICR 
9.9.2.1,  are shown in Figs. 5 a and b.  Examination of these two maps showed 
that the profiles of ICR 9.9.2.1 were not identical. In nine independent analyses, 
the number of distinct peaks generated from ICR 9.9.2.1 ranged from 41 to 52. 3 
We have therefore analyzed each map independently. For example, the first 
line of Table H summarizes the data for the map of ICR 16 vs. ICR 9.9.2.1. ICR 
16 had 46 peptide peaks: 36, or 75%, were shared with ICR 9.9.2.1; the extra 12, 
or 25%, were not found in ICR 9.9.2.1.  In this map, ICR 9.9.2.1 had 51 peptide 
peaks, of which the 36 shared with ICR 16 constituted 71%. 15 (29%) of the ICR 
9.9.2.1 peaks were not found in ICR 16. A similar analysis of the other maps, 
summarized in Table II, showed that ICR 9.9.2.1 differed from each variant by 
10% (ICR 9.9.1.6.7,  line h) to 29% (ICR 16). These differences were significantly 
smaller than the 50% difference found when ICR 9.9.2.1 was compared to the 
~2b parent, 45.6.2.4 (Table II, line i). These results, like our serological data, 
enabled us to distinguish the ~/2a variants, as a group, from the parent. 
The sensitivity of the peptide analysis allowed us to discriminate between the 
variants and to subdivide them according to their structural similarities. The 
variant that was most similar to ICR 9.9.2.1 was ICR 9.9.1.6.7  (Table HI, line 
a). Since both were secondary variants derived from the same primary variant 
(ICR 9), we thought that a comparison of other variants which arose by a single 
route might also show close similarities. Accordingly, ICR 4.68.66 was compared 
'-' T. Francus and B. K. Birshtein. Manuscript in preparation. 
3 So that a single map might yield as much information as possible, we have done the following: 
(a) we label with valine, threonine, and leucine, all of which are abundant in immunoglobulins, 
so that a  significant percentage of heavy chains might be accounted for,  and  (b) we  use both 
trypsin  and  chymotrypsin  to  solubilize  as  much  of the  protein  as  possible  and  to  facilitate 
chromatography. 
The lack of exact reproducibility of peptide profiles from map to map undoubtedly reflects the 
general problem of resolving numerous peptides and may additionally reflect the varying yields 
of chymotryptic cleavages.  However, use of double-labeled cleavage and maps gives an internal 
control to this method since a  single variant protein, independently labeled, gives identical 3H 
and ~C profiles under these conditions. FRANCUS~  DHARMGRONGARTAMA,  CAMPBELL,  SCHARFF~  AND  BIRSHTEIN  1543 
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FIG. 5.  Tryptic-chyrnotryptic  peptide map of  variant y2a heavy chains, a, [3H]ICR 9.9.2.1 
vs. [14C]ICR 16. b, [3H]ICR 9.9.2.1  vs. [14C]ICR 11.8.  Details of  preparation of  sample and 
chromatography of  peptides are described in Materials and Methods. 
with ICR 4.68.110,  both of which arose from the same short heavy chain (50,000 
mol wt)  producing  primary  variant  and  to ICR  11.19.3,  which arose  from a 
different short heavy  chain  (50,000  tool wt) producing primary  variant.  The 
results  in Table  III  (lines  b  and  c)  pointed  out the  similarities  in  all  three 
proteins and underscored a  closer structural relationship in the pair derived 
from the same primary variant  (ICR 4.68.66  and ICR 4.68.110).  Similarly,  we 
found that M224 and M319.2,  both primary variants obtained after Melphalan 
mutagenesis were almost indistinguishable.  (Table III, line d).  Another close 
structural relationship between the variants M224 and ICR 11.8, both primary 
variants derived after mutagenesis with two different mutagens, was suggested 
upon a close examination of their maps each vs.  ICR 9.9.2.1  (Table II, lines d 1544  NEW  SUBCLASS  EXPRESSION  IN  A  MOUSE  MYELOMA  CELL  LINE 
TABLE  II 
Compilation of Heavy Chain Peptide Map Analyses of Parent and T2a Variant Proteins 
vs. ICR 9.9.2.1 
Peptide peaks  Peptide peaks 
Protein source  Total  Total 
Shared no.  Extra no.  Shared  no.  Extra no. 
a. ICR 16  48  36 (75%)  12 (25%)  vs. ICR 9.9.2.1  51  36 (71%)  15 (29%) 
b.  ICR 11.19.2  36  31 (86%)  5 (14%)  "  42  31 (74%)  11 (26%) 
c. ICR 4.68.66  41  32 (78%)  9 (22%)  ....  41  32 (78%)  9 (22%) 
d. M224  39  36 (92%)  3 (8%)  ....  46  36 (78%)  10 (22%) 
e. M319.2  38  32 (84%)  6 (16%)  "  40  32 (80%)  8 (20%) 
f.  ICR 11.8  43  37 (86%)  6 (14%)  "  46  37 (80%)  9 (20%) 
g. U2  60  46 (75%)  15 (25%)  ....  52  45 (87%)  7 (13%) 
h. ICR 9.9.1.6.7  51  43 (84%)  8 (16%)  48  43 (90%)  5 (10%) 
i.  45.6.2.4  34  19 (56%)  15 (44%)  41  19 (46%)  22 (54%) 
TABLE  III 
Compilation of Heavy Chain Peptide Map Analysis of Pairs of Variants  Generated via 
the Same Route 
Peptide peaks  T2a Variant pro-  Peptide peaks 
T2a Variant pro-  Total  Total 
tein  tein 
Shared no.  Extra no.  Shared no.  Extra no 
a.  *ICR 9.9.1.6.7  51  43 (84%)  8  (16%)  vs.  ICR 9.9.2.1  48  43 (90%)  5  I10%) 
b.  ICR 4.68.66  39  36 (92%)  3  (8%)  vs  ICR 4.68.110  40  36 (90%)  4  (10%) 
c.  ICR 4.68.66  44  36 (82%)  8  (18%)  vs.  ICR 11.19.3  43  36  (84%)  7  (16%) 
d.  M224  49  49 (1(~}%)  -  vs.  M319.2  52  49 c94%)  3  ¢6%l 
e.  M224  47  45 196%)  2  14%)  vs.  ICR 11.8  46  45 (98%)  1 (2%) 
f,  M224 Fab  28  28 (100%)  -  vs.  ICR 11.8 Fab  28  28 (100%~ 
g.  M224 Fc  27  27 (100%)  -  vs.  ICR 11.8 Fab  27  27  ~100%) 
* These data are taken from Table II,  line h 
and f, Fig.  5b).  Direct comparison of their heavy chains  (Fig.  6), and their Fab 
and Fc fragments showed them to be strikingly similar if not identical  (Table 
III, lines e-g). 
Thus,  peptide map analyses have enabled us to subdivide the variants,  but 
the grouping that results does not completely correlate with their origin. 
Assembly Characteristics.  The major pathway used by any mouse myeloma 
tumor for the assembly of H2L2 from newly synthesized heavy and light chains 
depends on the subclass of the heavy chain that it makes (27). For example, T 2b 
producing tumors assemble their immunoglobulin mainly via H  +  L  --, HL + 
HL --~ H2L2,  while the major pathway in theT2a producing tumors is H  +  H  ---, 
H2 +  L -* H2L +  L ~  H2L2 (27). Our studies on the short heavy chain producing 
variants  further  supported  the  idea  that  the  structure  of the  heavy  chain 
dictates the assembly pattern: variants synthesizing heavy chains of 50,000 mol 
wt fail to assemble past the HL stage, while those synthesizing heavy chains of 
40,000 mol wt secrete both H2I¢ and HL (5). 
We asked whether we could discriminate among the T 2a variants by examin- 
ing  their  assembly characteristics  since  preliminary  pulse-chase  experiments 
had  shown that they might differ (S.  Koskimies and  B.  K.  Birshtein,  unpub- 
lished data). We labeled the ~/2a variants, the parent (MPC 11, T 2b), and LPC 1 
(~ 2a) cells for 15 min, and examined the radiolabeled immunoglobulin assembly FRANCUS,  DHARMGRONGARTAMA, CAMPBELL,  SCHARFF,  AND  BIRSHTEIN  1545 
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FIG. 6.  Tryptic-chymotryptic  peptide map of  heavy chains of  [3H]ICR 11.8  vs. [I'C]M224. 
Details  of  preparation of  sample and  chromatography of  peptides are  described in  Materials 
and Methods. 
pH 
FIo.  7.  Assembly patterns of ICR 4.68.66 (A) and ICR 11.8 (B) examined by SDS-PAGE 
and their densitometry tracing. Details are in Materials and Methods.  H, heavy chain; L, 
light chain; F, constant region of light chain. 
components by SDS-PAGE, as described in Materials and Methods. Fig. 7 shows 
differences in radioautographs and densitometric scans for two variants, ICR 
4.68.66(A) and ICR ll.8(B). 
The assembly patterns of the ~2a variants have been analyzed both for their 
rate of assembly to H2L2 and for their relative amount of HL (Fig. 8). As noted 
by Baumal et al. and as shown in Fig. 8 A-panels j and k, the relative amount 
of HL discriminates between ~2a and ~2b tumors, with ~/2a tumors, such as 
LPC 1 (panel j) having lower relative HL than a ~2b tumor, such as MPC 11 
(panel k). All the ~/2a variants are lower than MPC 11 in this parameter and 
are similar to LPC 1, implying that they, like ~ 2a producing tumors, do not use 1546  NEW  SUBCLASS  EXPRESSION  IN  A  MOUSE  MYELOMA  CELL  LINE 
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FIG.  8.  Assembly  patterns  of ~,2a producing  variants compared by normalized HL  (A), 
and normalized H~L~ (B).  a, ICR 4.68.66.  b, ICR 11.19.2.  c, ICR 16. d, ICR 11.8.  e, M224.  f, 
M319.2.  g, ICR 9.9.2.1.  h, ICR 9.9.1.6.7.  i,  U2. j, LPC  1 (~/2a control), k,  MPC 11  (parent 
~2b).  Variants were compared by using integration of densitometric traces. Calculations 
were normalized to only those assembly components containing heavy chains because of 
varying amounts of light  chains produced by different  variants;  e.g. normalized H2I~ = 
H~LJ(H2L2 + H2L + H.~ + HL); normalized HL = HL/(H2L.o + H.~L  + H~ + HL). 
the HL intermediate as their major pathway of assembly. 
Fig.  8 B shows the histogram of normalized H2L2 as a measure of the rate of 
assembly. ~2a producing variants are shown in panels a-i (ICR 4.68.66, panel a, 
and ICR 11.8, panel d) and the results of four determinations each of LPC 1 and 
MPC  11  are shown in panels j  and k,  respectively.  Visually,  the ~/2a variants 
differ from each other much more than the error of the procedure. Statistically, 
with 95% confidence, 4 we can say that the ~/2a variants fall into more than one 
group. Those variants having the fastest rate of assembly are ICR 4.68.66 (panel 
a), ICR 11.19.2  (panel b), and ICR 16 (panel c).  Of these three, ICR 4.68.66 and 
ICR 11.19.2,  both secondary  ~2a variants  derived from short heavy chain pro- 
ducing variants,  were previously grouped together on the basis of charge  and 
peptide maps; while ICR 16 has seemed to be the most distinctive of the ~2a pro- 
ducing variants because of its peptide profile (Fig.  5a)  (6). 
The  remaining  six  variants  (Fig.  8B,  panels  d-i)  have  a  similar  rate  of 
assembly which does not differ significantly from either MPC 11 b/2b) or LPC 1 
4 ~  =  H2LJ(H2L~  +  H~L  +  H2  +  HL)  =  fraction H2L~ is  of total  assembly components 
containing heavy chains; ]:~  =  HL/(H~L2  +  H2L +  H~  +  HL)= fraction HL is of total assembly 
components containing heavy chains; $12!~:~, S12~t-the variance of ]~2  and ~L, respectively, 
as calculated for the percent assembled H2L2 and HL from four independent labeling experiments 
of MPC  11.  The  subscript "1"  indicates control.  $22 M~--~, S22n~-the variance of ~  andS, 
respectively, in the nine variants studied for the percent assembled H2I~ and HL. Subscript "2" 
indicates variants.  FH---~  = S22H--~/S,~h-~ =  194.56/12.86  = 15.13; F~-L =  S~2~/S,2~  =  8.6/0.7  = 
12.28; critical value for 1~,  s  (8,  3)  =  8.84.  Since both F~h-~ and F~ are  >  8.84,  we can say at the 
95%+  confidence level that the variants fall into more than one assembly group. That is, under 
the null hypothesis that the variants fall into one group and assuming the experimental errors 
are the same for the variants and the controls, the true variance of the control ~r~2N-~ will equal 
the true variance of the variants a22 ~.  Similarly, ~1  ~  ~  will equal ¢r~  2  ~. The sample F  values 
of 15.13 and 12.28 allow us to reject the null hypothesis that the variants fall into one group. FRANCUS,  DHARMGRONGARTAMA, CAMPBELL,  SCHARFF,  AND  BIRSHTEIN  1547 
(,/2a).  It is noteworthy that ICR  11.8, M224, and M319.2 (panels d,  e  and fi 
respectively), the three variants that seem indistinguishable by peptide maps, 
assemble similarly. 
Discussion 
We have isolated from the y2b producing cell line, MPC 11, a dozen variants 
synthesizing immunoglobulins having a T2a serotype. The expression of the ~/2a 
structural  gene was  confirmed when we  showed that  the  Fc  region of one 
variant was identical to the Fc of the IgG2a immunoglobulin MOPC  173, and 
different from that of the IgG2b immunoglobulin, MPC 11 (7).  2 In this paper, we 
have shown,  by a  radioimmunoassay, that the idiotypes of the variants are 
identical to those of the parent. The simplest explanation for the generation of 
variants synthesizing heavy chains which have the parental  idiotype and a 
constant region of a  previously silent gene is a  translocation of the sort sug- 
gested by Gally and Edelman (28). This hypothesis would predict that all the 
y2a variants would be identical to each other. However, we showed that two 
y2a variants (M224 and ICR 16) differed extensively in their peptide profiles (6). 
This finding suggested that other genetic mechanisms must be involved. Any 
genetic mechanism proposed  must  take  into  account the  high  incidence of 
variants and the multiple routes by which they arose. Primary ~/2a producing 
variants generated by either ICR 191 or Melphalan occurred at an incidence of 
0.6-2%  (6) and secondary variants arose without further mutagenesis at the 
same frequency (9). 
Our  focus here was  to  define differences and  similarities among the y2a 
variants that might allow us to distinguish and group them and understand the 
genetic mechanisms of their origins. The major outcome of these studies has 
been the observation that these many ~/2a variant proteins differ from each 
other. However, our examination of the variants by charge, peptide maps and 
assembly characteristics has enabled us to subdivide them. Three of the primary 
variants-M224, M319.2 and ICR ll.8-are very similar by all our assays and, 
in fact, are almost indistinguishable by peptide maps. It should be emphasized 
that two of these variants arose after Melphalan mutagenesis and the other 
after  ICR-191 treatment.  This  group  might  thus  result  from  a  commonly 
operative mechanism in an immunoglobulin producing cell.  Translocation is 
one such mechanism, but only detailed structural studies will enable us to test 
this hypothesis. 
A second group is comprised of the secondary variants which arose from ICR 
4.68 and ICR 11.19, which are primary variants synthesizing short heavy chains 
of tool  wt 50,000. These secondary variants-ICR 4.68.66,  ICR 4.68.110,  ICR 
11.19.2 and ICR 11.19.3-were similar in charge and in assembly pattern. Their 
peptide maps showed extensive similarities; however, they are not identical. 
The rest of the variants do not fall into obvious groups. ICR 16 and ICR 9, 
both primary variants obtained after ICR 191 treatment, differ markedly from 
the other 72a variants, including ICR 11.8, which arose after identical treat- 
ment. ICR 16's structure is probably the most different of the ~/2a variants, as 
reflected by its peptide maps and its assembly pattern. ICR 9 is unique by virtue 
of its 75,000 tool wt heavy chain. The secondary variants derived from ICR 9- 
ICR 9.9.2.1 and ICR 9.9.1.6.7-could potentially comprise a group since their 
peptide maps show similarities; but their assembly patterns are rather different. 1548  NEW  SUBCLASS  EXPRESSION  IN  A  MOUSE  MYELOMA  CELL  LINE 
The spontaneously arising variant, U2,  differs in peptide map and assembly 
pattern and also falls outside of our groupings. Our finding that several 72a 
variants differ thus precludes strict translocation as a sole mechanism for their 
generation. 
We considered the possibility that the variants represent the expression of 
different ~/2a constant region genes which are ordinarily silent similar to the 
observation by Bosma and Bosma of the "wrong" allotype in a congenic mouse 
(29). However, our findings would seem to require more 72a constant region 
genes that one might propose on the basis of nucleic acid hybridization data for 
light  chain  genes.  In  addition,  Dr.  Melvin  Bosma  and  Ms.  Carol  DeWitt 
(unpublished  data)  showed  that  all  our  variants  carried  the  BALB/c  ~/2a 
aUotype. 
It is possible that all our variants could arise by a common mechanism, such 
as a series of recombination events between ~/2b and 72a constant region genes 
and that preferred sites of recombination Chot spots")  could explain the high 
frequency of some types of variants. By this mechanism, one would expect the 
variant heavy chains to be hybrid molecules containing varying lengths of~/2b 
and ~/2a constant region sequences. Such hybrid molecules have been reported 
(11-14). Thus far, we have not serologically detected any 72b determinants in 
these variants; nor have we found any ~/2b specific  residues in our sequence 
studies  of the  Fc  of one  variant,  ICR  9.9.2.1. Recently, however,  we  have 
identified such residues in  another ~/2a variant protein,  ICR  11.19.3  (M.  L. 
Greenberg, R. Campbell, and B. K. Birshtein, unpublished data). Whether our 
variants reflect the type of DNA sequence arrangements recently seen in genes 
coding for proteins as diverse as adenovirus, globin, and immunoglobulin (30, 
31) remains, of course, a tantalizing question. 
Knowledge  of the  primary  structure  of the  variants  should  help  us  to 
discriminate among these mechanisms and our grouping of the variants helps 
us to select particular ones to study in depth. In addition, studies at the nucleic 
acid level to look for gene rearrangements, such as those shown by Hozumi and 
Tonegawa (32), have also begun. 
Summary 
12  variant  cell  lines  producing  an  IgG2a(K) immunoglobulin derived via 
different routes from the IgG2b(K) synthesizing MPC  11  were studied. These 
variants all have the parental MPC 11 idiotype as shown by a radioimmunoas- 
say.  A  comparison of the  variants by  charge,  peptide  maps,  and  assembly 
patterns has shown that most of them differ from one another, and some can be 
grouped. 
One group consists of three primary variants generated with two mutagenic 
agents:  these three have almost indistinguishable peptide  maps.  Two other 
primary variants which arose in a similar fashion differ markedly from each 
other and from this group. A second group is comprised of the four secondary 
variants which arose from two short heavy chain producing primary variants. 
Other secondary variants and the one spontaneously arising variant cannot be 
grouped.  Possible  genetic mechanisms such  as  translocation,  expression of 
previously silent genes and recombination are discussed. FRANCUS,  DHARMGRONGARTAMA,  CAMPBELL,  SCHARFF,  AND  BIRSHTEIN  1549 
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